STSA Stock Overview
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines.
Satsuma Pharmaceuticals, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.89|
|52 Week High||US$8.08|
|52 Week Low||US$0.59|
|1 Month Change||-82.34%|
|3 Month Change||-85.86%|
|1 Year Change||-81.73%|
|3 Year Change||-93.77%|
|5 Year Change||n/a|
|Change since IPO||-94.71%|
Recent News & Updates
|STSA||US Pharmaceuticals||US Market|
Return vs Industry: STSA underperformed the US Pharmaceuticals industry which returned 9.9% over the past year.
Return vs Market: STSA underperformed the US Market which returned -18.5% over the past year.
|STSA Average Weekly Movement||26.2%|
|Pharmaceuticals Industry Average Movement||10.8%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: STSA is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 26% a week.
Volatility Over Time: STSA's weekly volatility has increased from 16% to 26% over the past year.
About the Company
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company’s lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Satsuma Pharmaceuticals, Inc. Fundamentals Summary
|STSA fundamental statistics|
Is STSA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|STSA income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.89|
|Net Profit Margin||0.00%|
How did STSA perform over the long term?See historical performance and comparison